Filing Details
ATOSSA THERAPEUTICS, INC. (NASDAQ:ATOS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 07, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:ATOS
ATOSSA THERAPEUTICS, INC. (ATOS) Files Quarterly Report for Q0
ATOSSA THERAPEUTICS, INC. (NASDAQ:ATOS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 07, 2026.
At publication ·
What changed
ATOSSA THERAPEUTICS, INC. (NASDAQ:ATOS) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Atossa Therapeutics filed its quarterly report (Form 10-Q) on August 7, 2026, providing unaudited financial statements and management commentary on recent business performance.
- The company's stock trades at $2.36 with a market capitalization of $116.9 million as of the filing date.
- The quarterly report includes updated risk factors and information about emerging business trends since the last annual filing, though specific revenue figures and financial results are not disclosed in this summary.
Market Context
ATOSSA THERAPEUTICS, INC.'s stock currently trades at $2.36 with a market capitalization of $116.9M.
The 10-Q provides ATOSSA THERAPEUTICS, INC.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for ATOSSA THERAPEUTICS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ATOS Stock Page
Frequently Asked Questions
Where can I read ATOS's SEC filings?
Browse all filings on our ATOS SEC filings page.
What types of SEC filings does ATOSSA THERAPEUTICS, INC. file?
Public companies like ATOSSA THERAPEUTICS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
